Clinical study of lung cancer based on imprinted gene detection

A prospective double-blind clinical study of pulmonary nodules based on imprinted gene detection

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035761

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-08-06

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:The gold standard for the diagnosis of lung cancer with pulmonary nodules is postoperative histopathological examination. The diagnostic method of this study is positive expression of im

Index test:imprinted&#32

gene&#32

detection

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Pulmonary nodules suspected of lung cancer (500 cases); 2. Aged >= 18 and = 0.8cm; 4. Indications for tissue biopsy (tracheoscopy or percutaneous lung puncture) or surgery.

Exclusion criteria

Exclusion criteria: 1. Patients who can not understand the research process, or are unable / unwilling to answer questionnaires, provide medical records, examination reports and other relevant information; 2. Patients who did not comply with the research work; 3. There was no pathological report.

Design outcomes

Primary

Measure	Time frame
imprinted gene;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactQi Wang

The Second Affiliated Hospital of Dalian Medical University

wqdlmu@163.com17709870005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026